Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Cymraeg
Cymraeg
Search
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
NICE TAs
NICE TAs
13/05/2025
TA1062: Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
08/05/2025
TA1060: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer
07/05/2025
TA1059: Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma
16/04/2025
TA1056: Molnupiravir for treating COVID-19
16/04/2025
TA1055: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
16/04/2025
TA1057: Relugolix–estradiol–norethisterone for treating symptoms of endometriosis
15/04/2025
TA1054: Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
15/04/2025
TA1053: Cladribine for treating active relapsing forms of multiple sclerosis
02/04/2025
TA1051: Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
27/03/2025
TA1050: Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
27/03/2025
TA1048: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable
27/03/2025
TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia
12/03/2025
TA1046: Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma
05/03/2025
TA1045: 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites
26/02/2025
TA1043: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
26/02/2025
TA1044: Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over
19/02/2025
TA1042: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
19/02/2025
TA1041: Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer
02/10/2024
TA1009: Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
17/09/2024
TA1007: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
1
2
3
4
5
6
7
8
9
10
11
Follow AWTTC: